SLL

A team working on technology innovation for the public good has been featured in an NPR technology story shared via Flipboard. One team member expressed pride in the collaboration and said a final full report would be submitted shortly after the upcoming election. The work appears to focus on using innovation in service of public-interest goals.

Pirtobrutinib has shown improved progression-free survival compared with bendamustine plus rituximab in patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The finding suggests the BTK inhibitor may become a new first-line option for blood cancer patients, and oncologists are weighing what it means for existing standard-of-care treatment choices.